Akebia Therapeutics — Corporate Update (March 2023)

6 slides from Akebia Therapeutics's corporate update, Mar 27, 2023

Slide 1: Update for Stockholders March 2023
Update for Stockholders March 2023
Slide 2: Forward-looking statements
Statements in this presentation regarding Akebia Therapeutics, Inc.’s (“Akebia’s”) strategy, plans, prospects, expectations, beliefs, intentions and goals are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and include, but are
Slide 3: A Commitment to Address Patients' Unmet Needs
A Commitment to Address Patients’ Unmet Needs
Slide 4: Maximize Value and Advance Innovation
Maximize Value and Advance Innovation 1 Auryxia® (ferric citrate) net product revenue - $177.1M for 2022 up 24.5% over 2021 Operating expense reduced year-over-year; reduction of excess purchase commitment liability of $67.6M Cash to fund operating plan expected for at least 12 months from Form 10-K
Slide 5: 2023 A Defining Year
2023 A Defining Year European Commission approval for vadadustat for dialysis dependent patients (May 2023) European vadadustat partnership Receive regulatory decision for vadadustat for U.K., Switzerland and Australia Receive decision on appeal process with FDA related to CRL for vadadustat Present
Slide 6: Akebia
Akebi —_ €8€6«CY be p